Altamira Therapeutics Ltd. Selling Expense
Altamira Therapeutics Ltd. (CYTOF) reported Selling Expense of $210.00 thousand for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-04-22.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:SellingExpense · last filed 2024-04-22
| Period end | Selling Expense 12 month |
|---|---|
| 2023-12-31 | $210.00K 20-F/A · filed 2024-04-22 |